MIVI Neuroscience, Inc., a US-based company that deals with next-generation neurointerventional medical devices, announced on Wednesday that it has completed enrolment for its clinical trial to evaluate the safety and effectiveness of the Q Revascularisation System to treat acute ischemic stroke (EVAQ Trial).

The EVAQ Trial has enrolled 121 subjects at 17 centres worldwide. Data from the study is to be utilised as part of an application to the US Food and Drug Administration (FDA) for market approval of the device in the US.

The Q Revascularisation System is designed to provide up to twice the aspiration power of traditional aspiration catheters. It combines the MIVI Q Aspiration Catheter with the MIVI Super 90 Guide Catheter.

Lucas Elijovich, MD, of Semmes-Murphey Neurologic Institute in Memphis, Tennesse, and principal US investigator, said, 'While aspiration catheters are used in nearly every stroke treatment, their design has not significantly changed over the last decade. The Q Aspiration Catheter is a novel design that delivers greater aspiration power without increasing the size of the catheter tip. This may be especially advantageous in smaller vessels, where large-bore catheters may not safely access and single-lumen catheters offer limited efficacy.'